JOURNEY MEDICAL CORP (DERM) Institutional Selling Activity
Several institutional investors tracked by InsiderSet reduced exposure to JOURNEY MEDICAL CORP (DERM) during the quarter ended June 30, 2026 based on sequential SEC Form 13F filings.
The largest disclosed institutional seller of DERM during the latest reporting period reduced its reported position by approximately $125,902 based on quarter-end filing values.
Institutional selling activity may reflect profit-taking, sector rotation, portfolio rebalancing, or changing conviction levels among major investment firms. InsiderSet tracks quarter-over-quarter holding reductions, full exits, estimated value changes, and historical selling activity using publicly disclosed SEC filing data.
The investors covered on this page collectively reduced approximately $290,719.417 in reported DERM exposure during the latest filing period, although many institutional holders continue to maintain significant long-term ownership positions in JOURNEY MEDICAL CORP.
| Portfolio quarter | Name | Type | Quantity | Remaining | Reported stock balance |
|---|---|---|---|---|---|
| Q2 2026 | Renaissance Technologies LLC | Sell | -12,800 | 229,700 | $1,626,276 |
| Q1 2026 | Renaissance Technologies LLC | Sell | -1,500 | 242,500 | $1,137,325 |
| Q4 2025 | Renaissance Technologies LLC | Sell | -3,900 | 244,000 | $1,881,240 |
| Q4 2024 | Renaissance Technologies LLC | Sell | -32,200 | 236,000 | $922,760 |
| Q2 2024 | Renaissance Technologies LLC | Sell | -6,575 | 264,025 | $1,489,101 |
| Q2 2023 | Renaissance Technologies LLC | Sell | -4,100 | 11,500 | $18 |
Frequently asked questions about DERM activity
Which institutional owners are buying DERM?
Institutional owners buying DERM include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.
What does "buy" mean in DERM activity?
"Buy" means an investor increased their reported position in DERM compared to the prior reporting period. This reflects growing exposure to JOURNEY MEDICAL CORP (DERM) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).
Is institutional interest in DERM increasing?
Institutional interest in DERM can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.